Wednesday, 26 August 2026European Markets

BENEVOLENTAI Stock Was 9.3% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BENEVOLENTAI (BAI.AS) jumping 9.3% to €1.41 on Wednesday, following the last session's upward trend. AEX-Index rose 1.63% to €768.14, after three consecutive sessions in a row of gains, on what was an all-around positive trend trading session today.

BENEVOLENTAI's last close was €1.29, 82.8% below its 52-week high of €7.50.

About BENEVOLENTAI

BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Earnings Per Share

As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.49.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -152.53%.

Volatility

BENEVOLENTAI's last week, last month's, and last quarter's current intraday variation average was a negative 1.77%, a negative 2.65%, and a positive 4.22%.

BENEVOLENTAI's highest amplitude of average volatility was 5.52% (last week), 3.91% (last month), and 4.22% (last quarter).

Volume

Today's last reported volume for BENEVOLENTAI is 1448 which is 34.82% above its average volume of 1074.

Moving Average

BENEVOLENTAI's worth is way below its 50-day moving average of €1.83 and way under its 200-day moving average of €3.07.

More news about BENEVOLENTAI (BAI.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com